Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of temsirolimus when given
together with sorafenib in treating patients with unresectable or metastatic solid tumors.
Sorafenib and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood
flow to the tumor. Giving sorafenib together with temsirolimus may kill more tumor cells.